Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III
trial in intermediate-risk (pN1) early breast cancer: efficacy and
predictive value of Ki67 expression (vol 25, pg 1551, 2014)
Dokumenttyp:
Correction
Autor(en):
Nitz, U.; Gluz, O.; Huober, J.; Kreipe, H. H.; Kates, R. E.; Hartmann, A.; Erber, R.; Moustafa, Z.; Scholz, M.; Lisboa, B.; Mohrmann, S.; Moebus, V.; Augustin, D.; Hoffmann, G.; Weiss, E.; Boehmer, S.; Kreienberg, R.; du Bois, A.; Sattler, D.; Thomssen, C.; Kiechle, M.; Jaenicke, F.; Wallwiener, D.; Harbeck, N.; Kuhn, W.